(Company No.: 420056-K)

# CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME FOR THE PERIOD ENDED 31 MAY 2022

	2022 Current Quarter Ended 31-May RM'000	2021 Comparative Quarter Ended 31-May RM'000	2022 Cumulative Year To Date 31-May RM'000	2021 Cumulative Year To Date 31-May RM'000
Income Revenue Cost of sales Gross Profit	1,091 (764) 327	3,150 (1,081) 2,069	12,227 (10,054) 2,173	25,457 (9,982) 15,475
Other income	349	8,703	582	2,653
Total Income	1,440	11,853	12,810	28,110
Expenses Selling and distribution Administrative and general expenses Profit / (Loss) from Operations (EBITA) Amortisation of Intangible Assets Depreciation Profit / (Loss) Before Interest, Taxes (EBIT),	(10) (4,005) (3,339) (913) (106)	(1) (1,016) 9,755 (932) (112)	(1,422) (8,720) (7,387) (3,652) (423)	(6) (3,367) 14,755 (3,653) (447)
Impairment and ESOS Expenses	(4,358)	8,711	(11,462)	10,655
ESOS Expenses Profit / (Loss) Before Interest and Taxes	(4,358)	(1,955) <b>6,756</b>	(361) ( <b>11,823)</b>	(6,585) <b>4,070</b>
Reversal of impairment loss on trade receivables Impairment loss on trade receivables Impairment loss on intangible assets <b>Profit / (Loss) Before Interest and Taxes</b>	(13,401) (9,779) <b>(27,538)</b>	(1,334) 	(13,401) (9,779) <b>(35,003)</b>	9,057 (1,340) - <b>11,787</b>
Finance Cost <b>Profit / (Loss) before Tax</b>	(25) (27,563)	(23) <b>5,399</b>	(98) ( <b>35,101)</b>	(99) <b>11,688</b>
Profit / (Loss) before tax is stated after charging/(crediting	g):-			
Interest income Reversal of impairment loss on trade receivables Impairment loss on trade receivables Impairment on intagible asset Depreciation and amortisation ESOS expenses Foreign exchange (gain) / loss	(17) - 13,401 9,779 1,019 - (44)	(35) (8,267) 1,334 - 1,044 1,955 (430)	(103) - 13,401 9,779 4,075 361 (1)	(51) (9,057) 1,340 - 4,100 (6,585) (75)
Income tax expense	_	-	-	(120)
Profit / (Loss) for the period	(27,563)	5,399	(35,101)	11,568
Foreign currency translation	748	274	1,185	(100)
Total Comprehensive Profit / (Loss)	(26,815)	5,673	(33,916)	11,468
Attributable to :- Owners of the Company Non-Controlling Interests	(27,563) -	5,399 -	(35,101) -	11,568 -

	(27,563)	5,399	(35,101)	11,568
Total comprehensive profit / (loss) attributable to:- Owners of the Company Non-Controlling Interests	(26,815)	5,673 -	(33,916) -	11,468 -
	(26,815)	5,673	(33,916)	11,468
Earnings / (Loss) per share - Basic (sen) - Diluted (sen)	(4.43) (4.41)	0.87 0.82	(5.64) (5.45)	2.18 2.13

Note:

The Condensed Consolidated Statements of Comprehensive Income should be read in conjunction with the audited financial statements for the period ended 31 May 2021 and the accompanying explanatory notes attached to the interim financial statements.

# UCREST BERHAD

(Company No.: 420056-K)

# CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS AT 31 MAY 2022

	As At 31 May 2022 RM'000	As At 31 May 2021 RM'000
ASSETS		
Non-Current Assets Property, Plant and Equipment Right-of-use Assets Intangible Assets Total Non-Current Assets	54 13 7,595 7,662	297 171 21,027 21,495
Current Assets Trade Receivables Other Receivables Tax Recoverable Deposits, Cash and Bank Balances Total Current Assets Total Assets	11,971 101 610 <u>15,487</u> 28,169 <b>35,831</b>	25,716 71 441 18,646 44,874 <b>66,369</b>
EQUITY AND LIABILITIES		
Capital and Reserves Share Capital Reserves Total Equity	45,912 (19,827) 26,085	45,912 13,728 59,640
Non-Current Liabilities Trade and Other Payables Total Non-Current Liabilities	<u>98</u> 98	98 98
Current Liabilities Trade Payables Other Payables Leased Liabilities Bank Overdraft Total Current Liabilities Total Liabilities	9,396 238 14 - <u>9,648</u> 9,746	6,238 216 177 - 6,631 6,729
Total Equity and Liabilities	35,831	66,369
Net Assets Per Share Attributable to owners of the Company (Sen)	4	10

Note:

The Condensed Consolidated Statement of Financial Position should be read in conjunction with the audited financial statements for the year ended 31 May 2021 and the accompanying explanatory notes attached to the interim financial statements.

# UCREST BERHAD

(Company No.: 420056-K)

# CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY FOR THE PERIOD ENDED 31 MAY 2022

		Foreign Currency			Equity Attributable	
	Share Capital RM'000	translation Reserve RM'000	ESOS Reserve RM'000	Accumulated Loss RM'000	to the Owners of the Company RM'000	Total Equity RM'000
Quarter ended 31 May 2022						
Balance as at 1 Jun 2021 (Audited), As previously stated	45,912	(11)	6,610	7,129	59,640	59,640
Issuance of shares	-	-	-	-	-	-
Share options granted under ESOS	-	-	361	-	361	361
Lapsed share options	-	-	(14)	14	-	-
Profit/(loss) for the period	-	1,185	-	(35,101)	(33,916)	(33,916)
Comprehensive profit/(loss) for the period	-	1,185	347	(35,087)	(33,555)	(33,555)
Balance as at 31 May 2022 (Unaudited)	45,912	1,174	6,957	(27,958)	26,085	26,085

Note:

The condensed consolidated statement of changes in equity should be read in conjunction with the audited financial statements for the year ended 31 May 2021 and the accompanying notes attached to the interim financial statements.

# UCREST BERHAD

(Company No.: 420056-K)

# CONDENSED CONSOLIDATED CASH FLOW STATEMENT FOR THE PERIOD ENDED 31 MAY 2022

	12 Months to date ended 31/05/2022 RM'000	12 Months to date ended 31/05/2021 RM'000
CASH FLOWS FROM OPERATING ACTIVITIES		
Profit / (Loss) before tax	(35,101)	11,688
Adjustments for:		
Amortisation of intangible assets	3,652	3,653
Depreciation of property, plant and equipment	265	289
Depreciation of right-of-use asset	158	158
Impairment loss on intangible assets	9,779	-
Impairment loss on trade receivables	13,401	1,340
Reversal of impairment loss on receivables	(220)	(9,057)
ESOS expenses	361	6,585
Finance costs	98	99
Interest income	(103)	(51)
Rent concession	- (22)	(16)
Unrealised gain on foreign exchange translation Unrealised loss on foreign exchange translation	(33) 32	(378) 303
Operating profit before changes in working capital	(7,711)	14,613
Changes in working capital:-	(r, r+1)	14,013
Inventories	-	-
Trade and other receivables	308	(3,191)
Trade and other payables	3,149	(15,464)
Cash used in operations	(4,254)	(4,042)
Interest received	103	51
Tax paid	(169)	(354)
Net cash generated from / (used in) operating activities	(4,320)	(4,345)
CASH FLOWS FROM INVESTING ACTIVITIES		
Purchase of property, plant & equipment	(22)	(7)
Net cash used in investing activities	(22)	(7)
CASH FLOWS FROM FINANCING ACTIVITIES		
Proceed from issuance of share capital		
- private placement	-	20,762
- pursuant to exercise of ESOS	-	1,954
Repatment to director	-	(604)
Repayment of lease liability	(164)	(150)
Interest paid	(98)	(4)
Net cash generated from / (used in) financing activities	(262)	21,958
NET INCREASE / (DECREASE) IN CASH AND CASH EQUIVALENTS	(4,604)	17,606
CASH AND CASH EQUIVALENTS AT 01 JUNE	18,646	1,538
EFFECTS OF EXCHANGE RATE CHANGES	1,445	(498)
CASH AND CASH EQUIVALENTS AS AT END OF THE FINANCIAL PERIOD	15,487	18,646

# Cash and cash equivalents

Cash and cash equivalents included in the statements of cash flows comprise the following statements of financial position amounts:

Deposits	4,048	11,048
Cash and bank balances	11,439	7,598
	15,487	18,646

Note:

The condensed consolidated cash flow statement should be read in conjunction with the audited financial statements for the year ended 31 May 2021 and the accompanying notes attached to the interim financial statements.

(Company No.: 420056-K)

# SELECTED EXPLANATORY NOTES

## 1. Accounting Policies and Methods Of Computation

The current quarter financial report ended 31 May 2022 is unaudited and has been prepared in accordance with Malaysian Financial Reporting Standards ("MFRS") 134 "Interim Financial Reporting" and Paragraph 9.22 of the Listing Requirements of Bursa Malaysia Securities Berhad ("Bursa Securities") for the ACE Market.

The report should be read in conjunction with the audited financial statements of the Group for the financial year ended 31 May 2021. The explanatory notes attached to the quarterly financial report provide an explanation on events and transactions that are significant to an understanding of the changes in the financial position and performance of the Group since the financial year ended 31 May 2021.

The accounting policies and methods of computation adopted by the Group in the quarterly financial report are consistent with those adopted in the audited financial statements of the Group for the financial year ended 31 May 2021.

#### 2. Auditors' Report on Preceding Annual Financial Statements

The auditors' report on the audited financial statements for the year ended 31 May 2021 was not qualified.

#### 3. Segmental Reporting

#### **Geographical information**

	Individual Qua	arter Ended	Individual YTD		
	31-May-22 RM'000	31-May-21 RM'000	31-May-22 RM'000	31-May-21 RM'000	
Malaysia	-	60	208	268	
International	1,091	3,090	12,019	25,189	
Group revenue	1,091	3,150	12,227	25,457	

#### 4. Unusual Items

During the quarter under review, there were no unusual items affecting assets, liabilities, equity, net income, or cash flows of the Group.

#### 5. Changes In Estimates Of Amount Reported Previously Affecting Current Interim Period

There are no changes in estimates of amount reported that will have a material effect in the current interim period.

### 6. Seasonality or Cyclicality

The operations of the Group are not subject to any seasonality or cyclicality factors.

#### 7. Dividends Paid Or Proposed

Dividends were neither paid nor proposed during the current interim period.

### 8. Valuation of Property, Plant and Equipment

The Group has not carried out any valuation on its property, plant & equipment.

### 9. Debts and Equity Securities

There were no issuances, cancellations, repurchases, resale and repayments of debt and equity securities.

# 10. Change In The Composition of The Group

There has been no change in the composition of the group for the quarter review.

### SELECTED EXPLANATORY NOTES

### **11. Discontinued Operation**

There were no discontinued operations within the activities of the Group for the quarter under review.

#### 12. Capital Commitments

There were no capital commitments for the purchase of any property, plant and equipment or any other expenses that were not accounted for in the financial statements of the quarter under review.

### 13. Changes In Contingent Liabilities & Assets

There are no material contingent liabilities as at the date of this report.

### 14. Subsequent Events

There were no material events subsequent to the end of the reporting quarter that have not been reflected in the quarter under review.

### Additional Information As Per ACE Market Listing Requirement

#### 15. Review Of Performance

During the current quarter under review, the Group recorded a net loss attributable to Owners of the Company of RM27.563 million.

### 16. Material Change In the Profit / (Loss) Before Taxation Compared To The Results of :-

	Immediate Preceding Quarter		Individual Qu	arter Ended	Individual YTD	
	31-May-22 RM'000	28-Feb-22 RM'000	31-May-22 RM'000	31-May-21 RM'000	31-May-22 RM'000	31-May-21 RM'000
P/(L)BITDA	(3,339)	(3,082)	(3,339)	9,755	(7,387)	14,755
Less : Amortisation of intangible assets	(913)	(913)	(913)	(932)	(3,652)	(3,653)
Less : Depreciation	(106)	(106)	(106)	(112)	(423)	(447)
Less : ESOS expenses	-	-	-	(1,955)	(361)	(6,585)
Less : Impairment los on trade receivables	(13,401)	-	(13,401)	(1,334)	(13,401)	(1,340)
Less : Impairment los on intangible assets	(9,779)	-	(9,779)	-	(9,779)	-
Less : Finance cost	(25)	(25)	(25)	(23)	(98)	(99)
Add: Reversal of impairment loss on trade receiv	-	-	-	-	-	9,057
Profit / (Loss) before tax	(27,563)	(4,126)	(27,563)	5,399	(35,101)	11,688

The Group recorded loss before tax of RM 27.563 million in the current quarter, and loss before tax of RM 4.126 million in the immediate preceding quarter.

### **17. Commentary Of Prospects**

iMedic HRP in Singapore has been extended amid recent spike of COVID-19 BA.5 cases, the utilization has increased. Budget of telemedicine for the Government hospitals that were suspended during the pandemic is returning and the Group see significant increase in the engagement for iMedic business in the recent months, hence, the revenue is expected to increase in FY2023. There are several partnership engagement with the pharmaceutical companies and distributors that the Group is working on closing in the coming months. The Group has terminated its agreements on the production of Sputnik due to the change in the pandemic.

### **18. Profit Forecast**

There was no profit forecast issued by the Group.

# SELECTED EXPLANATORY NOTES

# 19. Taxation

There wew no tax provision during the current interim period under review.

#### 20. Unquoted Investments / Properties

There were no purchase or sales of unquoted investments or properties during the current interim period under review.

#### 21. Purchase or Disposal of Quoted Securities

There were no purchase or disposal of quoted securities during the current interim period under review.

#### 22. Status of Corporate Proposal

The Company had at the Extraordinary General Meeting held on 22 January 2018 obtained the shareholders' approval for a private placement exercise to issue up to 106,901,642 new ordinary shares in the Company representing not more than twenty percent (20%) of the issued share capital of the company ("Private Placement").

94,303,575 new Ordinary Shares were issued pursuant to the Private Placement and were subsequently listed and quoted on the Ace Market of Bursa Malaysia Securities Berhad.

The details of the utilisation of proceeds from the Private Placement were as follows:-

Description	Proposed Utilisation (RM'000)	Actual Utilisation (RM'000)	Balance to be utilized (RM'000)
Payment for cost of sales	11,328	11,328	0
Payment of salaries	1,285	1,285	0
Payment of office rentals	161	161	0

The Proposed Private Placement is deemed completed on 17 December 2020.

The Company had at the Annual General Meeting held on 17 November 2020 obtained the shareholders' approval for a private placement exercise to issue up to 126,857,800 new ordinary shares in the Company representing not more than twenty percent (20%) of the issued share capital of the company ("Private Placement"). Subsequently, the Company had at the Annual General Meeting held on 12 November 2021 obtained the shareholders' approval for a general mandate to issued up to ten percent (10%) of its total number of issued shares.

As at the date of this report, 42,700,000 new Ordinary Shares were issued pursuant to the Private Placement and were subsequently listed and quoted on the Ace Market of Bursa Malaysia Securities Berhad.

The details of the utilisation of proceeds from the Private Placement were as follows:-

Description	Proposed Utilisation (RM'000)	Actual Utilisation (RM'000)	Balance to be utilized (RM'000)
Working capital	20,748	7,898	12,850
Expenses for the proposed private placement	184	90	94

#### 23. Group Borrowings and Debt Securities

There were no borrowings and debts securities for the financial quarter under review.

# 24. Off Balance Sheet Financial Instruments

There were no off balance sheet financial instruments as at the date of this report.

#### 25. Material Litigation

There were no Material Litigation for the financial quarter under review.

# SELECTED EXPLANATORY NOTES

### 26. Realised and Unrealised Profits/Losses

On 25 March 2010, Bursa Securities issued a directive to all listed issuers pursuant to Rules 2.07 and 2.23 of Bursa Securities ACE Market Listing Requirements. The directive requires all listed issuers to disclose the breakdown of the unappropriated profits or accumulated losses as at the end of the reporting period, into realised and unrealised profits and losses.

On 20 December 2010, Bursa Securities further issued guidance on the disclose and the format period.

The breakdown of accumulated profit / (losses) of the Group as at the reporting date, into realised and unrealised losses, pursuant to the directive, is as follows:

	Gro	up
	<u>Unaudited</u>	Audited
	31/05/2022	31/05/2021
	RM'000	RM'000
Total accumulated profit / (losses) of UCrest Berhad and it's subsidiaries:		
- Realised	(27,957)	7,432
- Unrealised - in respect of other items of income and expense	(1)	(303)
Total Group accumulated profit as per consolidated accounts	(27,958)	7,129

The determination of realised and unrealised losses is based on the Guidedance of Special Matter No.1, Determination of Realised and Unrealised Profits or Losses in the Context of Disclosure Pursuant to Bursa Malaysia Securities Berhad Listing Requirements, issued by the Malaysian Institute of Accountants on 20 December 2010.

The disclosure of realised and unrealised losses above is solely for complying with the disclosure requirements stipulated in the directive of Bursa Malaysia and should not be applied for any other purposes.

### 27. Dividends Payable

The Board of Directors does not recommend any interim dividends for the current quarter ended 31 May 2022.

# 28. Earnings / (Loss) Per Share

(a) Basic

The basic earnings / (loss) per share for the quarter and cumulative year to date are computed as follow:

	Individual quarter ended		<u>Cumulati</u>	ive YTD
	<u>Unaudited</u> 31-May-22	<u>Unaudited</u> 31-May-21	<u>Unaudited</u> 31-May-22	<u>Audited</u> 31-May-21
Net profit / (loss) attributable to owners of the company (RM'000)	(27,563)	5,399	(35,101)	11,568
Weighted average number of ordinary shares in issue ('000)	621,877	621,877	621,877	531,211
Basic earnings / (loss) per share (sen)	(4.43)	0.87	(5.64)	2.18

(b) Diluted

The diluted earning / (loss) per share for the quarter and cumulative year to date are computed as follow:

	Individual quarter ended		Cumulative YTD	
	<u>Unaudited</u> 31-May-22	<u>Unaudited</u> 31-May-21	Unaudited 31-May-22	<u>Audited</u> 31-May-21
Net profit / (loss) attributable to owners of the company (RM'000)	(27,563)	5,399	(35,101)	11,568
Dilutive shares on option outstanding ('000)	624,484	659,807	644,116	544,422
Diluted earnings / (loss) per share (sen)	(4.41)	0.82	(5.45)	2.13